Breo Ellipta 100-25mcg Oral Inh(30)

Manufacturer GLAXO SMITH KLINE Active Ingredient Fluticasone and Vilanterol(floo TIK a sone & VYE lan ter ol) Pronunciation FLOOT-ih-ka-sone & VYE-lan-ter-ol
It is used to treat COPD (chronic obstructive pulmonary disease).It is used to treat asthma.Do not use this drug to treat intense flare- ups of shortness of breath. Use a rescue inhaler. If you have questions, talk with the doctor.
🏷️
Drug Class
Corticosteroid/Long-acting beta2-adrenergic agonist (LABA) combination
🧬
Pharmacologic Class
Inhaled corticosteroid (ICS) / Long-acting beta2-adrenergic agonist (LABA)
🀰
Pregnancy Category
Category C
βœ…
FDA Approved
May 2013
βš–οΈ
DEA Schedule
Not Controlled

Overview

ℹ️

What is this medicine?

Breo Ellipta is an inhaled medicine that contains two active ingredients: a corticosteroid (fluticasone) and a long-acting bronchodilator (vilanterol). It is used once daily to help control symptoms of asthma and chronic obstructive pulmonary disease (COPD), such as wheezing, shortness of breath, and coughing. The corticosteroid helps reduce inflammation in your lungs, and the bronchodilator helps open up your airways, making it easier to breathe. It is not for sudden breathing problems.
πŸ“‹

How to Use This Medicine

Taking Your Medication Correctly

To use this medication effectively, follow your doctor's instructions and read all accompanying information carefully. This medication is for inhalation only. Take it at the same time every day to establish a routine. Continue using the medication as directed by your doctor or healthcare provider, even if you start feeling better.

Important Usage Instructions

Do not remove the inhaler from its foil tray until you are ready to use it for the first time.
After each dose, close the device to preserve the medication and prevent contamination. Only open the device when you are ready to take a dose.
Avoid taking the device apart or washing it, as this can damage the mechanism and affect the medication's potency.
Do not use this inhaler with a spacer, as it is designed for direct inhalation.
Refrain from breathing out into the device to prevent moisture buildup and maintain the medication's effectiveness.
After each use, rinse your mouth with water to remove any residual medication. Do not swallow the rinse water; instead, spit it out.

Using Multiple Inhaled Medications

If you are using more than one inhaled medication, consult your doctor to determine which medication to use first. This will help you establish a safe and effective routine.

Storing and Disposing of Your Medication

Store your inhaler at room temperature in a dry place, away from bathrooms and areas exposed to heat and sunlight. The inhaler features a dose counter to track the number of doses remaining. Dispose of the inhaler when the counter reaches "0", six weeks after opening the foil container, or after the expiration date, whichever occurs first.

Missing a Dose

If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at the same time or use extra doses to make up for a missed dose.
πŸ’‘

Lifestyle & Tips

  • Use Breo Ellipta exactly as prescribed, once daily, at the same time each day.
  • Do not use Breo Ellipta for sudden breathing problems; use your rescue inhaler for acute symptoms.
  • Rinse your mouth with water and spit it out after each dose to help prevent oral thrush (a fungal infection in the mouth). Do not swallow the water.
  • Do not stop using Breo Ellipta suddenly without talking to your doctor, even if you feel better.
  • Avoid exposure to irritants that can trigger your asthma or COPD symptoms (e.g., smoke, allergens, air pollution).
  • Maintain good hydration and nutrition.
  • Get regular exercise as tolerated and recommended by your doctor.
  • Follow up with your doctor regularly to monitor your lung function and overall health.

Dosing & Administration

πŸ‘¨β€βš•οΈ

Adult Dosing

Standard Dose: One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily
Dose Range: 100 - 200 mg

Condition-Specific Dosing:

COPD: One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily
Asthma: One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) or (200 mcg fluticasone furoate / 25 mcg vilanterol) once daily
πŸ‘Ά

Pediatric Dosing

Neonatal: Not established
Infant: Not established
Child: Not established for children under 12 years of age
Adolescent: For asthma in patients 12 years and older: One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) or (200 mcg fluticasone furoate / 25 mcg vilanterol) once daily
βš•οΈ

Dose Adjustments

Renal Impairment:

Mild: No dosage adjustment necessary
Moderate: No dosage adjustment necessary
Severe: No dosage adjustment necessary
Dialysis: No dosage adjustment necessary

Hepatic Impairment:

Mild: No dosage adjustment necessary
Moderate: Consider 100 mcg/25 mcg once daily. Monitor for systemic corticosteroid effects.
Severe: Consider 100 mcg/25 mcg once daily. Monitor for systemic corticosteroid effects.

Pharmacology

πŸ”¬

Mechanism of Action

Breo Ellipta contains fluticasone furoate and vilanterol. Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It works by binding to glucocorticoid receptors, inhibiting inflammatory cells (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and the release of inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines). This reduces airway hyperresponsiveness and inflammation. Vilanterol is a long-acting beta2-adrenergic agonist (LABA). It acts locally in the lungs as a bronchodilator by stimulating beta2-adrenergic receptors on airway smooth muscle, leading to relaxation of the smooth muscle and bronchodilation. The combination provides both anti-inflammatory and bronchodilator effects.
πŸ“Š

Pharmacokinetics

Absorption:

Bioavailability: Fluticasone furoate: <1% (oral), 15.2% (inhaled); Vilanterol: <2% (oral), 27.8% (inhaled)
Tmax: Fluticasone furoate: 0.5-1 hour; Vilanterol: 5-10 minutes
FoodEffect: Not applicable for inhaled administration

Distribution:

Vd: Fluticasone furoate: 661 L; Vilanterol: 165 L
ProteinBinding: Fluticasone furoate: >99%; Vilanterol: >99%
CnssPenetration: Limited

Elimination:

HalfLife: Fluticasone furoate: ~24 hours; Vilanterol: ~11 hours
Clearance: Fluticasone furoate: 65.4 L/hr; Vilanterol: 108 L/hr
ExcretionRoute: Fluticasone furoate: Primarily feces (major), urine (minor); Vilanterol: Primarily feces (major), urine (minor)
Unchanged: Fluticasone furoate: <1% (urine); Vilanterol: <2% (urine)
⏱️

Pharmacodynamics

OnsetOfAction: Vilanterol: Within minutes (typically 15-20 minutes)
PeakEffect: Vilanterol: 1-2 hours
DurationOfAction: 24 hours (once daily dosing)

Safety & Warnings

⚠️

BLACK BOX WARNING

Long-acting beta2-adrenergic agonists (LABAs), such as vilanterol, increase the risk of asthma-related death. Data from a large, randomized, placebo-controlled clinical trial in asthma showed that LABAs increase the risk of asthma-related death. This finding is considered a class effect of LABAs. The safety and effectiveness of Breo Ellipta in patients with asthma have not been established. Breo Ellipta is not indicated for the primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required. Breo Ellipta should not be used more often than recommended, at higher doses than recommended, or with other LABA-containing products.
⚠️

Side Effects

Urgent Side Effects: Seek Medical Help Right Away

Although rare, this medication can cause severe and potentially life-threatening side effects. If you experience any of the following symptoms, contact your doctor or seek medical attention immediately:

Signs of an allergic reaction: rash, hives, itching, red, swollen, blistered, or peeling skin (with or without fever), wheezing, tightness in the chest or throat, trouble breathing, swallowing, or talking, unusual hoarseness, or swelling of the mouth, face, lips, tongue, or throat
Signs of infection: fever, chills, severe sore throat, ear or sinus pain, cough, increased or changed sputum production, painful urination, mouth sores, or a wound that won't heal
Signs of high blood sugar: confusion, drowsiness, excessive thirst or hunger, frequent urination, flushing, rapid breathing, or fruity-smelling breath
Signs of low potassium levels: muscle pain or weakness, muscle cramps, or an irregular heartbeat
Signs of a weak adrenal gland: severe nausea or vomiting, severe dizziness or fainting, muscle weakness, extreme fatigue, mood changes, decreased appetite, or weight loss
Signs of high blood pressure: severe headache or dizziness, fainting, or changes in vision
Chest pain or pressure, or a rapid heartbeat
Shakiness or tremors
Feeling nervous or excitable
Bone pain
Changes in vision, eye pain, or severe eye irritation
Mouth irritation or mouth sores
Redness or white patches in the mouth or throat
Feeling extremely tired or weak

Respiratory Emergency

This medication can cause severe breathing problems, which may be life-threatening. If you experience trouble breathing, worsening breathing, wheezing, or coughing after taking this medication, use a rescue inhaler and seek medical help immediately.

Other Possible Side Effects

Like all medications, this drug can cause side effects. While many people may not experience any side effects or only minor ones, it's essential to discuss any concerns with your doctor. If you experience any of the following side effects or any other symptoms that bother you or don't go away, contact your doctor:

Headache
Runny nose
Nose or throat irritation
Common cold symptoms
Flu-like symptoms
Changes in voice
Back pain
Joint pain

This is not an exhaustive list of possible side effects. If you have questions or concerns, contact your doctor. You can also report side effects to the FDA at 1-800-332-1088 or online at https://www.fda.gov/medwatch.
🚨

Seek Immediate Medical Attention If You Experience:

  • Worsening breathing problems or increased need for your rescue inhaler
  • Chest pain or fast/irregular heartbeat
  • Severe headache or dizziness
  • Tremor or nervousness
  • Muscle cramps
  • Signs of infection (fever, chills, body aches, increased mucus, change in mucus color)
  • White patches in your mouth or throat (oral thrush)
  • Blurred vision or other eye problems
  • Signs of an allergic reaction (rash, hives, swelling of face/lips/tongue, difficulty breathing/swallowing)
  • Unusual tiredness, weakness, nausea, vomiting, or lightheadedness (signs of adrenal insufficiency)
πŸ“‹

Before Using This Medicine

Before Taking This Medication: Important Information to Share with Your Doctor

It is essential to inform your doctor about the following:

Any allergies you have, including allergies to this medication, its components, or other substances, such as foods or drugs. Be sure to describe the symptoms you experienced.
If you have a milk allergy.
* If you are currently taking another medication similar to this one. If you are unsure, consult your doctor or pharmacist.

This list is not exhaustive, and it is crucial to discuss all your medications (including prescription, over-the-counter, natural products, and vitamins) and health conditions with your doctor and pharmacist. They will help determine if it is safe to take this medication with your other medications and health conditions.

Remember, do not start, stop, or change the dose of any medication without first consulting your doctor.
⚠️

Precautions & Cautions

Important Warnings and Cautions for Patients Taking This Medication

It is essential to inform all your healthcare providers, including doctors, nurses, pharmacists, and dentists, that you are taking this medication.

Blood Sugar Control
If you have diabetes (high blood sugar), this medication may cause your blood sugar levels to rise. Discuss with your doctor how to maintain control over your blood sugar levels.

Respiratory Problems
If your breathing problems worsen, your rescue inhaler is less effective, or you need to use it more frequently, contact your doctor immediately.

Dosage and Administration
Do not exceed the prescribed dose or use this medication more often than directed. Overdose can be fatal. Consult your doctor if you have any concerns.

Transitioning from Oral Steroids
When switching from an oral steroid to another form of steroid, you may be at risk for severe and potentially life-threatening side effects. Monitor for symptoms such as weakness, fatigue, dizziness, nausea, vomiting, confusion, or low blood sugar, and contact your doctor immediately if you experience any of these signs.

Stressful Situations
In cases of severe injury, surgery, or infection, you may require additional doses of oral steroids to help your body cope with stress. Carry a warning card indicating that you may need extra steroids in such situations.

Long-term Use and Eye Health
Prolonged use of this medication may increase the risk of developing cataracts or glaucoma. Discuss this with your doctor and follow their recommendations for regular eye exams.

Bone Health
Long-term use of this medication may also lead to weak bones (osteoporosis). Consult your doctor to assess your risk and discuss any concerns. Have a bone density test as advised by your doctor.

Infection Risk
You may be more susceptible to infections while taking this medication. Practice good hygiene by washing your hands frequently, and avoid close contact with people who have infections, colds, or flu.

Viral Infections
Chickenpox and measles can be severe or even fatal in individuals taking steroid medications like this one. Avoid exposure to anyone with these conditions if you have not had them before. If you have been exposed, contact your doctor.

Growth and Development in Children and Teens
This medication may affect growth in some cases. Regular growth checks may be necessary. Discuss this with your doctor.

Pregnancy and Breastfeeding
If you are pregnant, plan to become pregnant, or are breastfeeding, consult your doctor to weigh the benefits and risks to you and your baby.

COPD Patients
If you have Chronic Obstructive Pulmonary Disease (COPD), you are at a higher risk of developing pneumonia, which can be severe or even fatal. This medication may also increase the likelihood of hospitalization due to pneumonia. Discuss this with your doctor.
πŸ†˜

Overdose Information

Overdose Symptoms:

  • Chest pain
  • Fast or irregular heartbeat (tachycardia, arrhythmias)
  • Palpitations
  • Tremor
  • Nervousness
  • Headache
  • Dizziness
  • Nausea
  • Fatigue
  • Malaise
  • Hypokalemia
  • Hyperglycemia
  • Exaggerated systemic corticosteroid effects (e.g., Cushingoid features, adrenal suppression)

What to Do:

Seek immediate medical attention. Call 911 or your local emergency number. For poison control, call 1-800-222-1222. Treatment is supportive and symptomatic. Monitor cardiac function (ECG), serum potassium, and blood glucose. Consider judicious use of a cardioselective beta-blocker for cardiovascular effects, but only with extreme caution due to potential for bronchospasm.

Drug Interactions

πŸ”΄

Major Interactions

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin, itraconazole, cobicistat-containing products): May significantly increase systemic exposure to fluticasone furoate and vilanterol, leading to increased risk of cardiovascular and systemic corticosteroid adverse effects.
  • Beta-blockers (non-cardioselective): May block the bronchodilatory effect of vilanterol and produce severe bronchospasm in patients with COPD or asthma. Cardioselective beta-blockers should be used with caution.
🟑

Moderate Interactions

  • Diuretics (non-potassium-sparing): ECG changes and/or hypokalemia resulting from non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially at higher doses. Use with caution.
  • Tricyclic antidepressants (TCAs) and Monoamine Oxidase Inhibitors (MAOIs): May potentiate the effect of vilanterol on the cardiovascular system. Administer with extreme caution to patients being treated with MAOIs or TCAs, or within 2 weeks of discontinuation of such agents.
🟒

Minor Interactions

  • Other sympathomimetics: Concomitant administration may potentiate adverse cardiovascular effects. Use with caution.

Monitoring

πŸ”¬

Baseline Monitoring

Pulmonary function tests (FEV1)

Rationale: To establish baseline lung function and assess disease severity.

Timing: Prior to initiation of therapy

Medical history (including cardiovascular disease, glaucoma, cataracts, diabetes, osteoporosis, infections)

Rationale: To identify contraindications, precautions, and potential risks.

Timing: Prior to initiation of therapy

Electrolytes (Potassium)

Rationale: LABAs can cause hypokalemia.

Timing: Prior to initiation, especially in patients at risk

πŸ“Š

Routine Monitoring

Pulmonary function tests (FEV1)

Frequency: Periodically (e.g., every 3-6 months or as clinically indicated)

Target: Improvement from baseline, maintenance of optimal lung function

Action Threshold: Worsening FEV1, increased symptoms, or lack of improvement may indicate need for re-evaluation of therapy.

Signs and symptoms of asthma/COPD control

Frequency: At each clinical visit

Target: Reduced exacerbations, decreased rescue inhaler use, improved quality of life

Action Threshold: Increased frequency of symptoms, increased rescue inhaler use, or exacerbations.

Signs and symptoms of systemic corticosteroid effects (e.g., adrenal suppression, Cushing's syndrome, growth velocity in children, bone mineral density)

Frequency: Periodically, especially with higher doses or long-term use

Target: Absence of signs/symptoms

Action Threshold: Presence of signs/symptoms (e.g., weight gain, moon face, easy bruising, growth deceleration, bone pain).

Ocular examination (for glaucoma/cataracts)

Frequency: Annually or as clinically indicated, especially in patients with risk factors or long-term use

Target: Normal intraocular pressure, absence of cataracts

Action Threshold: Increased intraocular pressure, visual changes.

Blood glucose

Frequency: Periodically, especially in diabetic patients or those at risk

Target: Within target range

Action Threshold: Hyperglycemia.

Electrolytes (Potassium)

Frequency: Periodically, especially in patients at risk for hypokalemia

Target: Normal range

Action Threshold: Hypokalemia.

πŸ‘οΈ

Symptom Monitoring

  • Worsening shortness of breath
  • Increased wheezing
  • Increased cough
  • Increased need for rescue inhaler
  • Chest pain or palpitations
  • Tremor
  • Nervousness
  • Muscle cramps
  • Vision changes
  • Oral thrush (white patches in mouth/throat)
  • Hoarseness
  • Signs of infection (fever, chills, increased sputum)

Special Patient Groups

🀰

Pregnancy

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Poorly controlled asthma in pregnancy is associated with risks to both mother and fetus. There are no adequate and well-controlled studies of Breo Ellipta in pregnant women. Animal studies have shown reproductive toxicity with both fluticasone furoate and vilanterol.

Trimester-Specific Risks:

First Trimester: Potential for teratogenicity, though human data for inhaled corticosteroids generally reassuring. Vilanterol animal studies showed skeletal variations.
Second Trimester: Risk of fetal growth restriction with high doses of corticosteroids. Vilanterol animal studies showed skeletal variations.
Third Trimester: Risk of neonatal adrenal suppression with high doses of corticosteroids. LABAs may interfere with uterine contractility.
🀱

Lactation

It is unknown if fluticasone furoate or vilanterol are excreted in human milk. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for Breo Ellipta and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition. Fluticasone furoate and vilanterol are detected in the milk of lactating rats.

Infant Risk: Low systemic exposure in the mother suggests low levels in breast milk, but potential for adverse effects on infant (e.g., growth suppression, adrenal suppression) cannot be ruled out, especially with high doses. Monitor for signs of systemic corticosteroid effects or beta-agonist effects in the infant.
πŸ‘Ά

Pediatric Use

Breo Ellipta is approved for asthma in patients 12 years and older. Safety and effectiveness in children younger than 12 years of age have not been established. Inhaled corticosteroids can cause a reduction in growth velocity in pediatric patients. Monitor growth in pediatric patients receiving Breo Ellipta.

πŸ‘΄

Geriatric Use

No overall differences in safety or effectiveness were observed between elderly patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Dosage adjustment based on age alone is not necessary.

Clinical Information

πŸ’Ž

Clinical Pearls

  • Breo Ellipta is a once-daily maintenance treatment for asthma and COPD, not for acute bronchospasm.
  • Patients should be instructed to rinse their mouth with water and spit after each dose to reduce the risk of oral candidiasis (thrush).
  • Emphasize the importance of consistent daily use, even when symptoms are well-controlled.
  • Warn patients about the black box warning regarding the increased risk of asthma-related death with LABA monotherapy, and clarify that Breo Ellipta is a combination product and should not be used with other LABA-containing products.
  • Monitor for signs of systemic corticosteroid effects, especially with long-term use or higher doses, including adrenal suppression, bone mineral density changes, and ocular effects (glaucoma, cataracts).
  • Caution should be exercised when co-administering with strong CYP3A4 inhibitors due to increased systemic exposure of both components.
  • Patients should carry a rescue inhaler for acute symptoms and understand that Breo Ellipta is not a rescue medication.
πŸ”„

Alternative Therapies

  • Inhaled Corticosteroids (ICS) monotherapy (e.g., fluticasone propionate, budesonide, mometasone)
  • Long-acting Beta2-Adrenergic Agonists (LABA) monotherapy (e.g., salmeterol, formoterol, indacaterol, olodaterol) - *Note: LABA monotherapy is generally not recommended for asthma due to black box warning, but may be used for COPD.*
  • Long-acting Muscarinic Antagonists (LAMA) monotherapy (e.g., tiotropium, umeclidinium, glycopyrronium)
  • Oral corticosteroids (for severe exacerbations or refractory cases)
  • Leukotriene receptor antagonists (e.g., montelukast)
  • Phosphodiesterase-4 inhibitors (e.g., roflumilast - for severe COPD)
  • Biologics (e.g., omalizumab, mepolizumab, benralizumab, dupilumab - for severe asthma)
πŸ’°

Cost & Coverage

Average Cost: $300 - $400 per 30 doses
Insurance Coverage: Tier 2 or Tier 3 (Preferred or Non-Preferred Brand)
πŸ“š

General Drug Facts

If your symptoms or health issues persist or worsen, it's essential to contact your doctor for further guidance. To ensure your safety, never share your medication with others or take someone else's medication. Some medications may come with an additional patient information leaflet, so be sure to check with your pharmacist for more information. If you have any questions or concerns about your medication, don't hesitate to reach out to your doctor, nurse, pharmacist, or other healthcare provider. In the event of a suspected overdose, immediately call your local poison control center or seek medical attention. When seeking help, be prepared to provide details about the medication, including the amount taken and the time it happened, to ensure you receive the best possible care.